CLRB - Company ID 0001279704
The table below shows Cellectar Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $4.56M | $3.01M | $2.52M | $2.39M | $3.43M | $5.49M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.64M |
| $2.79M |
| $2.33M |
| $3.65M |
| $2.97M |
| $7.83M |
| Operating income | -$7.20M | -$5.79M | -$4.85M | -$6.04M | -$6.40M | -$13.33M |
| Income tax | - | - | - | - | - | - |
| Net income | -$6.93M | -$5.65M | -$4.44M | -$5.45M | -$6.60M | -$14.66M |
| EPS (diluted) | -$0.57 | -$1.33 | -$1.41 | -$3.39 | -$4.30 | -$12.13 |